NeXstar Pharmaceuticals' AmBisome Is Subject Of Two Talks At ICAAC

September 17, 1996

AmBisome NeXstar Pharmaceuticals, Inc.
2860 Wilderness Pl., Boulder, CO 80301
Phone 303.444.5893 Fax 303.444.0672

Contacts at NeXstar Pharmaceuticals:
Joseph Alper
Director, Corporate Communications
(303) 546-7717
Katy Doherty
Manager, Media Relations
(303) 546-7889

Independent European investigators today will present data from two multi-center, phase III comparative clinical trials conducted with AmBisome, NeXstar Pharmaceuticals' liposomal formulation of amphotericin B. The presentations will be made this afternoon in New Orleans during the session "Progress in Antifungal Therapy and Prevention" at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

NeXstar Pharmaceuticals and its U.S. development and marketing partner Fujisawa USA have decided to include the data from these studies in its U.S. New Drug Application for AmBisome. The two companies expect to complete the NDA filing within the next several weeks.

In the first presentation, A.C.A.P. Leenders, M.D., of the University Hospital Rotterdam, in The Netherlands, will describe the results of a study in which AmBisome was compared to amphotericin B as a treatment for cryptococcal meningitis in HIV- infected patients. Cryptococcal meningitis is a potentially life- threatening infection of the lining that surrounds the brain and of the cerebral spinal fluid (CSF).

In the paper to be presented, the investigators conclude that "[AmBisome] will sterilize the CSF significantly earlier than 0.7 mg/kg [of amphotericin B], that it has at least equal clinical efficacy and a significantly lower rate of nephrotoxicity when used for the treatment of cryptococcal meningitis in HIV infected patients." The mean time to sterilization of the CSF was 14 days for AmBisome, compared to more than 21 days for amphotericin B.

In the second presentation, Michael Ellis, M.D., a member of the European Organisation for the Research and Treatment of Cancer (EORTC), will detail the results of a randomized, multi-center study of low- and high-dose AmBisome therapy in the treatment of invasive aspergillosis. In this study of 119 cancer patients with impaired immune systems, the investigators found that treatment with low-dose AmBisome for a median of 20 days produced a response of 68 percent. In a separate talk at the same session on antifungal therapy, a team of U.S. investigators will present data from a multi-center study showing that the response rate for conventional amphotericin B therapy of invasive aspergillosis was 24 percent.

NeXstar Pharmaceuticals, Inc. is an integrated pharmaceutical company engaged in the discovery, development, manufacturing and marketing of products to treat life-threatening diseases. The Company currently markets two drugs, AmBisome and DaunoXome. The Company has headquarters in Boulder, Colorado; research, development and manufacturing facilities in San Dimas, California; Antwerp, Belgium; Lakewood, Colorado, and Boulder; and marketing subsidiaries worldwide.

Note for editors: This press release is available on our Web site at. After viewing the press release at this site you can save it as a text file for further use.

NeXstar Pharmaceuticals

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to